Physician profile
Nicholas A Demonaco
NPI 1871535245
$12,439.37
in general payments reported to CMS, 2019-2025
77 companies · $2,314 in 2025
The $2,314 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $425 · 2021: $291 · 2022: $2,063 · 2023: $4,129 · 2024: $2,505 · 2025: $2,314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,948.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $983.07 | 2019-2025 | Talvey, Tecvayli, Darzalex |
| Novartis Pharmaceuticals Corporation | $974.91 | 2019-2025 | |
| Daiichi Sankyo INC. | $749.89 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Pfizer INC. | $746.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $729.86 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $562.39 | 2019-2025 | Polivy, Lunsumio, Venclexta |
| Astrazeneca Pharmaceuticals LP | $457.37 | 2019-2025 | Enhertu, Imfinzi, Calquence |
| Abbvie INC. | $359.40 | 2022-2025 | Venclexta |
| Seagen INC. | $358.09 | 2019-2023 | Tivdak, Padcev, Adcetris |
| Astellas Pharma US INC | $335.01 | 2020-2025 | Padcev, Xtandi, Vyloy |
| Incyte Corporation | $327.13 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| E.R. Squibb & Sons, L.L.C. | $275.81 | 2019-2025 | Eliquis, Opdivo, Augtyro |
| Bayer Healthcare Pharmaceuticals INC. | $264.11 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $260.92 | 2019-2023 | Imbruvica, Epkinly |
| Lilly USA, LLC | $217.88 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $216.50 | 2022-2025 | Iclusig, Fruzaqla, Advate |
| Eisai INC. | $215.08 | 2019-2025 | |
| Genzyme Corporation | $203.99 | 2021-2023 | |
| Pharmaessentia USA Corporation | $202.08 | 2022-2024 | Besremi |
| Exelixis INC. | $177.99 | 2023-2025 | Cabometyx |
| Beigene USA, INC. | $174.83 | 2022-2024 | Brukinsa |
| Celgene Corporation | $173.18 | 2020-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $161.37 | 2023-2025 | Jemperli, Zejula, Shingrix |
| Amgen INC. | $153.26 | 2021-2023 | Blincyto, Kyprolis, Evenity |
| Puma Biotechnology, INC. | $150.19 | 2020-2025 | Nerlynx |
| Sumitomo Pharma America, INC. | $146.12 | 2023-2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $144.40 | 2020-2025 | Ultomiris |
| Array Biopharma INC | $134.59 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Stemline Therapeutics INC. | $130.32 | 2023-2025 | Orserdu |
| Adaptive Biotechnologies Corporation | $123.21 | 2022-2025 | Clonoseq |
| Genmab U.S., INC. | $117.36 | 2023-2025 | Epkinly |
| Boston Scientific Corporation | $105.78 | 2019 | |
| Blueprint Medicines Corporation | $104.12 | 2022-2023 | Ayvakit |
| Taiho Oncology, INC. | $96.65 | 2023-2025 | |
| Tersera Therapeutics LLC | $93.96 | 2019-2023 | Xermelo |
| Regeneron Healthcare Solutions, INC. | $85.25 | 2022-2023 | Libtayo |
| Mirati Therapeutics, INC. | $83.08 | 2023-2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $80.82 | 2022-2023 | Tavalisse, Rezlidhia |
| Gilead Sciences, INC. | $80.58 | 2019-2025 | Trodelvy |
| Kyowa Kirin, INC. | $78.62 | 2022-2024 | Poteligeo |
| Beone Medicines USA, INC. | $78.37 | 2025 | Tevimbra, Brukinsa |
| Sobi, INC | $73.14 | 2022-2025 | |
| Morphosys, US INC. | $72.30 | 2023 | Monjuvi |
| Myovant Sciences INC. | $71.45 | 2021-2022 | |
| Adc Therapeutics America, INC. | $69.33 | 2023-2025 | |
| Servier Pharmaceuticals LLC | $66.65 | 2024-2025 | |
| Foundation Medicine, INC. | $55.61 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $54.79 | 2024-2025 | Somatuline Depot, Onivyde |
| Tempus Ai, INC | $49.04 | 2024 | Xt Cdx |
| Spectrum Pharmaceuticals INC. | $47.63 | 2023-2024 | Rolvedon |
| Cti Biopharma Corp. | $47.44 | 2022-2023 | Vonjo |
| Pharmacosmos Therapeutics INC. | $44.44 | 2022-2023 | Monoferric |
| Dendreon Pharmaceuticals LLC | $44.39 | 2024-2025 | Provenge |
| Caris Mpi, INC. | $43.18 | 2025 | Mi Cancer Seek |
| Emd Serono, INC. | $42.57 | 2023-2024 | Tepmetko |
| Deciphera Pharmaceuticals INC. | $40.49 | 2025 | Qinlock, Tgct, Romvimza |
| G1 Therapeutics, INC. | $40.34 | 2022 | |
| Coherus Oncology, INC. | $39.31 | 2023-2024 | |
| Blue Earth Diagnostics | $34.70 | 2023 | |
| Amag Pharmaceuticals, INC. | $33.30 | 2019 | |
| Myriad Genetic Laboratories, INC. | $32.99 | 2022-2024 | Myrisk |
| Acrotech Biopharma INC. | $30.55 | 2024-2025 | Beleodaq |
| Alnylam Pharmaceuticals INC. | $29.65 | 2023-2025 | Givlaari |
| Sirtex Medical INC | $26.93 | 2024 | Sir-Spheres Microspheres |
| Global Blood Therapeutics, INC. | $26.46 | 2022 | |
| Springworks Therapeutics, INC. | $22.90 | 2024 | Ogsiveo |
| Janssen Pharmaceuticals, INC | $22.79 | 2019 | |
| Fresenius Kabi USA, LLC | $22.54 | 2025 | |
| Accord Healthcare, INC. | $21.26 | 2025 | |
| Eusa Pharma (US) LLC | $21.24 | 2022 | |
| Dova Pharmaceuticals | $20.87 | 2021 | |
| Celltrion USA INC. | $19.73 | 2024 | Vegzelma |
| Aveo Pharmaceuticals, INC. | $15.50 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.80 | 2025 | |
| Horizon Therapeutics Plc | $14.03 | 2019 | |
| Secura Bio, INC. | $12.78 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Demonaco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.